1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need

 
• By Bowman Cox

Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.

Corona patient
covid-19 epidemic severely tests us pharma supply chain

Hospital pharmacies are making do as best they can with a fitful supply chain for critical COVID-19 medicines, one that has stumbled on manufacturing quality issues in recent years and is having difficulty meeting immediate needs as the coronavirus epidemic surges in places like the New York City metropolitan area.

What is at the top of the wish list for these pharmacies is “availability of those first- and second-line drugs in the vial sizes that make sense for those areas that need them immediately,” Michael Ganio, senior director, pharmacy practice and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.

More from Compliance